Company Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
9.19 ^USD	-5.94%		-0.65%	-46.10%

May. 07	Neumora Therapeutics Shares Fall as Q1 Loss Narrows	MT
May. 07	Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Companyâs therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Number of employees: 120

Managers	Title	Age	Since
Carol Suh FOU	Founder	33	19-10-31
Henry Gosebruch CEO	Chief Executive Officer	51	23-07-17
Paul Berns FOU	Founder	57	19-10-31
Joshua Pinto DFI	Director of Finance/CFO	38	21-05-31
Raj Manchanda CTO	Chief Tech/Sci/R&D Officer	58	23-06-30
Nicholas Brandon CTO	Chief Tech/Sci/R&D Officer	50	20-03-31
Robert Lenz CTO	Chief Tech/Sci/R&D Officer	-	23-10-09
Maryjo Chamberlain-Tharp PRN	Corporate Officer/Principal	48	21-07-31
Amy Sullivan HRO	Human Resources Officer	-	20-12-31
Lori Houle PRN	Corporate Officer/Principal	57	21-03-31

Members of the board	Title	Age	Since
Paul Berns FOU	Founder	57	19-10-31
May Kin Ho BRD	Director/Board Member	71	21-03-31
Kristina Burow BRD	Director/Board Member	50	19-12-31
Matthew Fust BRD	Director/Board Member	59	20-11-30
Henry Gosebruch CEO	Chief Executive Officer	51	23-07-17
Alaa Halawa BRD	Director/Board Member	42	21-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	159,523,997	114,732,490 ( 71.92 %)	0	71.92 %

Name	Equities	%	Valuation
Biomatics Capital Management CO LLC 4.948 %	7,861,859	4.948 %	108 M $
SoftBank Capital Partners LLC 4.813 %	7,646,916	4.813 %	105 M $
Paul Berns 4.813 %	7,646,916	4.813 %	105 M $
Impresa Management LLC 3.540 %	5,624,353	3.540 %	77 M $
MIC Capital Management UK LLP 2.807 %	4,460,700	2.807 %	61 M $
ICONIQ Capital LLC 2.139 %	3,398,628	2.139 %	47 M $
Wellcome Trust Ltd. (Direct Investments) 2.083 %	3,309,123	2.083 %	46 M $
Artal Group SA 1.607 %	2,552,702	1.607 %	35 M $
EcoR1 Capital, LLC 1.304 %	2,071,450	1.304 %	28 M $
Avidity Partners Management LP 1.253 %	1,990,632	1.253 %	27 M $

Neumora Therapeutics, Inc.

490 Arsenal Way Suite 200

02472, Watertown

http://www.neumoratx.com

address Neumora Therapeutics, Inc.(NMRA)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.19 USD

Average target price

24.71 USD

Spread / Average Target

+168.90%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUMORA THERAPEUTICS, INC.	-46.10%	1.47B
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research